{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:35Z","timestamp":1781654015804,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gastroesophageal junction (GEJ) cancer has remained a significant global health challenge due to late-stage diagnosis and poor survival outcomes. This study presents the 10-year institutional experience in the multimodal management of non-metastatic GEJ cancer in a low-resource setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective cohort study of 101 patients with non-metastatic GEJ cancer. Data on demographics, tumor characteristics, management approach, and outcomes were analyzed. Outcomes of patients who underwent neoadjuvant therapy versus outright surgery were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Majority of the patients were males (76%), with a mean age of 56 years old (SD 11.6) and adenocarcinoma as the predominant histology (85%). Of the cohort, 40% underwent neoadjuvant therapy, predominantly FLOT chemotherapy regimen (37%) and CROSS chemoradiotherapy regimen (54%). Definitive surgery primarily left thoracoabdominal approach with distal esophagectomy and total gastrectomy, and Roux-en-y esophagojejunostomy was performed in 60% of the cases. Neoadjuvant therapy was associated with reduced margin positivity and improved tumor regression; however, it had a high rate of incomplete treatment due to toxicity or progression. Surgical and medical complications occurred in 18% and 26%, respectively, with a 7% in-hospital mortality rate. The overall survival was 14%, and the 2- and 5-year cancer-specific survival was higher in the neoadjuvant group compared to upfront surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study underscores the benefits of a multimodal treatment strategy in non-metastatic GEJ cancer; however, challenges, including low institutional surgical volumes and treatment-related toxicity, highlight areas for improvement. Strengthening multidisciplinary collaboration and access to advanced systemic therapies are essential to optimize patient outcomes in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-025-04190-6","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:15:19Z","timestamp":1770192919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative management of non-metastatic gastroesophageal cancer in a Philippine university hospital: a 10-year experience"],"prefix":"10.1186","volume":"24","author":[{"given":"Dawn Andrea N.","family":"Fontanar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiela S.","family":"Macalindong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"1","key":"4190_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1759-7714.14745","volume":"14","author":"C Liu","year":"2022","unstructured":"Liu C, Ma Y, Qin Q, et al. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thorac Cancer. 2022;14(1):3\u201311. https:\/\/doi.org\/10.1111\/1759-7714.14745.","journal-title":"Thorac Cancer"},{"issue":"1","key":"4190_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jtho.2016.10.016","volume":"12","author":"TW Rice","year":"2017","unstructured":"Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol. 2017;12(1):36\u201342. https:\/\/doi.org\/10.1016\/j.jtho.2016.10.016.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4190_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semradonc.2012.09.008","volume":"23","author":"MF Buas","year":"2013","unstructured":"Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23(1):3\u20139. https:\/\/doi.org\/10.1016\/j.semradonc.2012.09.008.","journal-title":"Semin Radiat Oncol"},{"issue":"10184","key":"4190_CR4","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"issue":"18","key":"4190_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, Van Lanschot JJB, Hulshof MCCM, et al. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: the randomized controlled CROSS Trial. JCO. 2021;39(18):1995\u20132004. https:\/\/doi.org\/10.1200\/JCO.20.03614.","journal-title":"JCO"},{"key":"4190_CR6","doi-asserted-by":"publisher","unstructured":"Macalindong SS, Dela Pe\u00f1a AS, Buckley B. Ten-year review of patients with resected esophagogastric junction adenocarcinoma in the Philippine general hospital. Acta Med Philipp Published Online Dec. 2020;13. https:\/\/doi.org\/10.47895\/amp.vi0.2452.","DOI":"10.47895\/amp.vi0.2452"},{"issue":"5","key":"4190_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/biom13050796","volume":"13","author":"JJ Li","year":"2023","unstructured":"Li JJ, Rogers JE, Yamashita K, Waters RE, Murphy MB, Ajani JA. Therapeutic advances in the treatment of gastroesophageal cancers. Biomolecules. 2023;13(5):796. https:\/\/doi.org\/10.3390\/biom13050796.","journal-title":"Biomolecules"},{"issue":"2","key":"4190_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14740\/wjon1254","volume":"11","author":"EO Then","year":"2020","unstructured":"Then EO, Lopez M, Saleem S, et al. Esophageal Cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol. 2020;11(2):55. https:\/\/doi.org\/10.14740\/wjon1254.","journal-title":"World J Oncol"},{"issue":"8","key":"4190_CR9","doi-asserted-by":"publisher","first-page":"830","DOI":"10.6004\/jnccn.2011.0072","volume":"9","author":"JA Ajani","year":"2011","unstructured":"Ajani JA, Barthel JS, Bentrem DJ, et al. Esophageal and Esophagogastric Junction Cancers. J Natl Compr Canc Netw. 2011;9(8):830\u201387. https:\/\/doi.org\/10.6004\/jnccn.2011.0072.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"4190_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020288","volume":"16","author":"M Oberoi","year":"2024","unstructured":"Oberoi M, Noor MS, Abdelfatah E. The multidisciplinary approach and surgical management of GE junction adenocarcinoma. Cancers. 2024;16(2):288. https:\/\/doi.org\/10.3390\/cancers16020288.","journal-title":"Cancers"},{"issue":"5","key":"4190_CR11","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1245\/s10434-019-08176-z","volume":"27","author":"CJR Schlick","year":"2020","unstructured":"Schlick CJR, Khorfan R, Odell DD, Merkow RP, Bentrem DJ. Margin positivity in resectable esophageal cancer: are there modifiable risk factors? Ann Surg Oncol. 2020;27(5):1496\u2013507. https:\/\/doi.org\/10.1245\/s10434-019-08176-z.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4190_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1245\/s10434-011-1945-3","volume":"19","author":"RP Merkow","year":"2012","unstructured":"Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Ko CY, Bentrem DJ. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. Ann Surg Oncol. 2012;19(2):357\u201364. https:\/\/doi.org\/10.1245\/s10434-011-1945-3.","journal-title":"Ann Surg Oncol"},{"key":"4190_CR13","unstructured":"Esophageal Resection for Cancer | Hospital and Surgery Center Ratings | Leapfrog Group. https:\/\/ratings.leapfroggroup.org\/measure\/hospital\/2024\/esophageal-resection-cancer. Accessed 26 Nov 2024."},{"key":"4190_CR14","unstructured":"National Comprehensive Cancer Network. Esophageal and Esophagogastric Junction Cancers. (Version 4. 2024). https:\/\/www.nccn.org\/guidelines\/category_1. Accessed 25 Nov 2024."},{"issue":"10","key":"4190_CR15","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992\u20131004. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.003.","journal-title":"Ann Oncol"},{"issue":"4","key":"4190_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7076","volume":"13","author":"CE Gaber","year":"2024","unstructured":"Gaber CE, Sarker J, Abdelaziz AI, et al. Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: a systematic review and meta-analysis. Cancer Med. 2024;13(4):e7076. https:\/\/doi.org\/10.1002\/cam4.7076.","journal-title":"Cancer Med"},{"key":"4190_CR17","doi-asserted-by":"publisher","unstructured":"Ubels S, Verstegen MHP, Rosman C, Reynolds JV. Anastomotic leakage after esophagectomy for esophageal cancer: risk factors and operative treatment. Annals Esophagus. 2021;4(0). https:\/\/doi.org\/10.21037\/aoe-2020-18.","DOI":"10.21037\/aoe-2020-18"},{"issue":"7","key":"4190_CR18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/dote.12251","volume":"28","author":"B Mungo","year":"2015","unstructured":"Mungo B, Molena D, Stem M, et al. <article-title update=\"added\">Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality?: Esophagectomy after induction therapy. Dis Esophagus. 2015;28(7):644\u201351. https:\/\/doi.org\/10.1111\/dote.12251.","journal-title":"Dis Esophagus"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04190-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04190-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04190-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:04:13Z","timestamp":1781651053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04190-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4190"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04190-6","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of the Philippines Manila Research Ethics Board (UPMREB 2024-0489-01) prior to commencement of the study. Human Ethics and Consent to Participate declarations were not applicable in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}